Godavari Drugs Limited approved working capital limits aggregating up to ₹340 million from ICICI Bank Limited during its board meeting held on October 14, 2026.

The Board of Directors considered and authorized the availing of these facilities on the terms and conditions set out in the Credit Arrangement Letter dated October 12, 2026, issued by ICICI Bank. The approval also covers any temporary overdraft facility or temporary accommodation sanctioned by the bank in case of exigencies, along with the creation of security for the said facilities as stipulated by the lender.

Authorization and Execution

The board granted specific authority to Mukund Kakani, Managing Director, to accept the Credit Arrangement Letter, negotiate and finalize the terms, and execute all necessary facility and security documents required to give effect to the approval.

Regulatory Compliance

The company confirmed that the approved facilities fall within the borrowing limits previously authorized by the members under Section 180(1)(c) of the Companies Act, 2013. This authorization was granted via a Special Resolution passed at the Annual General Meeting held on May 16, 2022.

The meeting commenced at 4:00 pm and concluded at 4:30 pm at the registered office in Secunderabad, Telangana.

Godavari Drugs Limited confirmed that all four resolutions proposed at its 38th Annual General Meeting (AGM) held on September 25, 2026, were passed by shareholders. The meeting approved the inclusion of nutraceuticals in the company's main objects clause and ratified the appointment of cost auditors.

The voting results, submitted to BSE on September 26, 2026, showed overwhelming support from both promoters and public shareholders. A total of 4,337,679 votes were polled across all resolutions, with 4,336,109 votes cast in favour, representing 99.96% of the total valid votes. Only 1,570 votes were recorded against specific items.

Meeting proceedings and attendance

The 38th AGM was conducted via video conferencing and other audio-visual means. While the existing article noted 86 members attended, the scrutinizer's report clarifies that 86 members participated through video conferencing (9 promoters and 77 public shareholders). No shareholders attended in person or through proxies.

The board composition remained consistent with previous disclosures:

Resolutions passed

Shareholders voted on four key items of business. The audited standalone financial statements for FY26 were adopted without qualifications. The following resolutions were put to vote and passed:

1. Adoption of audited standalone financial statements for FY26.
2. Re-appointment of Ghanshyam Jaju as a director retiring by rotation.
3. Ratification of remuneration of ₹40,000 payable to M/s Bharathula & Associates as Cost Auditors for FY27.
4. Alteration of the Main Objects Clause of the Memorandum of Association to include nutraceuticals and dietary supplements.

Strategic expansion into nutraceuticals

A special resolution was passed to alter the company's main objects clause. This amendment allows Godavari Drugs to engage in the manufacture, processing, formulation, purchase, sale, import, export, marketing, and distribution of nutraceuticals, dietary supplements, health supplements, natural extracts, herbal extracts, botanical extracts, standardized plant extracts, food ingredients, food additives, functional foods, and allied products.

This move signals a strategic diversification beyond traditional pharmaceutical intermediates into the growing consumer health and wellness sector. The inclusion of these activities in the main objects clause provides the regulatory framework necessary for future investments and operations in this domain.

What the numbers show

While the AGM focused on governance and strategic updates rather than detailed financial breakdowns, two key operational indicators stand out. First, the proximity of the DHDT facility to commercial production suggests a potential near-term revenue driver, assuming supply chain logistics align with demand. Second, the formal inclusion of nutraceuticals in the object clause indicates a medium-term strategic pivot. Unlike a simple product launch, this legal amendment prepares the corporate structure for broader market entry, implying significant planned capital allocation or partnership opportunities in the consumer health space.